Can weight loss injections help with PCOS?

What's happening in PCOS that makes weight management so central?

Polycystic ovary syndrome is a hormonal condition, but insulin resistance sits at the core of it for most women who have it. Elevated insulin drives the ovaries to produce more androgens, which disrupts the normal cycle of follicle development and ovulation. It is a reinforcing loop: weight gain can worsen insulin resistance, and insulin resistance makes weight loss significantly harder. That is why standard dietary advice often produces frustratingly slow results in PCOS, the biology is working against a straightforward energy-deficit approach.

GLP-1 receptor agonists like semaglutide, and the dual GIP/GLP-1 agonist tirzepatide, act partly by improving insulin sensitivity and slowing gastric emptying. In people with type 2 diabetes, these effects on blood sugar regulation are well-established. In PCOS, the same mechanisms appear to be relevant: smaller studies and observational data suggest that GLP-1 medicines can reduce androgen levels, improve menstrual frequency, and support ovulation resumption alongside the weight reduction they produce. The relationship between PCOS and weight loss injections is an active area of clinical interest, even if the large phase-3 trials that established these medicines were not designed with PCOS as a primary endpoint. What you find in the evidence, then, is a plausible and promising mechanism backed by solid supporting data, but not yet the kind of PCOS-specific randomised trial a specialist would ideally want.

NHS guidance on weight management acknowledges the broader relationship between body weight, insulin, and hormonal disorders, and the NHS overview of tirzepatide provides general information on how the medicine works and what to expect.

Which injections are actually licensed, and does PCOS qualify you?

This is the part of the decision where precision matters. Mounjaro (tirzepatide) and Wegovy (semaglutide injection) are both licensed in the UK for weight management in adults, not specifically for PCOS. The licensing criteria are BMI of 30 or above, or BMI of 27 to 29.9 alongside at least one weight-related condition. PCOS itself is not listed among the weight-related conditions in the summary of product characteristics for either medicine; conditions more typically cited include hypertension, dyslipidaemia, obstructive sleep apnoea, and type 2 diabetes.

In practice, if you have PCOS and a BMI that meets the threshold, and you also have one of those listed conditions alongside it, you may well meet the licensed eligibility criteria on the basis of that co-existing condition. If PCOS is your only additional diagnosis and your BMI is in the 27–29.9 range, the prescriber's assessment becomes more careful. A BMI of 30 or above, by contrast, meets the standalone threshold regardless of the PCOS. Lower thresholds can apply for some ethnic backgrounds under UK clinical guidance (2.5 kg/m² lower, so 27.5 instead of 30, for example) which is worth raising in your consultation.

None of this means the medicine cannot be prescribed in a PCOS context. It means the prescriber frames the indication correctly and considers the whole picture. Our clinical team reviews every consultation personally, and complex situations like PCOS are handled by a real clinician, not automated criteria-matching.

What's genuinely uncertain, and the reproductive planning conversation you need to have

Honesty about the gaps matters here. The benefits of weight loss for PCOS are well-supported; the specific effects of GLP-1 medicines on PCOS markers beyond weight reduction are still being characterised. Some data suggests improvements in AMH levels, testosterone, and LH/FSH ratios with GLP-1 use in PCOS, but study sizes are small and follow-up periods short. It would not be accurate to say these medicines treat PCOS directly; they treat the weight and metabolic environment in which PCOS tends to worsen.

The reproductive planning question is serious and must not be glossed over. GLP-1 medicines are not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. If fertility is your primary goal and weight loss is a step towards fertility treatment, you should discuss the timing and wash-out requirements with your reproductive medicine specialist as well as your prescriber. For women using oral contraceptives, tirzepatide specifically requires an additional non-oral contraceptive method for the first four weeks of treatment and for four weeks after each dose increase, because the medicine's effect on gastric emptying can reduce pill absorption. That is documented in NHS England's guidance on weight management injections and is a practical detail worth acting on from day one.

One practical note on routine: these pens are stored in the fridge, so slotting the pen into the fridge door when you get home (alongside whatever else lives there) is one of the simplest ways to remember your weekly dose. If you want to understand storage requirements before deciding, the guide to storing weight loss injections covers the basics clearly.

Making the actual decision: who to involve and what to ask

If you have PCOS and are considering a weight loss injection, the most useful first step is a consultation that acknowledges the PCOS context explicitly, rather than treating weight management as though the hormonal dimension does not exist. Your GP or a specialist in reproductive endocrinology can speak to the PCOS management side; a prescriber at a regulated pharmacy can assess your eligibility for the medicines themselves. In some situations (particularly where fertility is actively on the agenda) both conversations need to happen before anything starts.

For a broader overview of what these medicines involve practically, our guide to injections to help with weight loss sets out the mechanism, the side-effect profile, and the process clearly. If you want to understand how the options compare for this specific condition, there is more detail on which weight loss injection suits PCOS best. Side effects to be aware of include nausea, vomiting, diarrhoea, and constipation, particularly in the earlier weeks; the MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk is where to report anything unexpected.

At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber the same day, a real clinician who can weigh your PCOS history alongside the standard eligibility criteria. If you are ready to have that conversation, you can speak to our prescribers through a free consultation, and they will give you a straight answer about whether this is an appropriate route for you. You can also read more about the injections that help with weight loss to get a clearer sense of what each option involves before your appointment.